[1] |
LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin.
Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
|
[2] |
LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang.
Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
|
[3] |
LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong.
Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
|
[4] |
LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang.
Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
|
[5] |
XIE Xiangmei, HUANG Zhihong, LIU Xiaoju, XUE Bing, LAN Baozhu.
Effects of atorvastatin and folic acid tablets on homocysteine and carotid atherosclerosis in patients with type H hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 455-459.
|
[6] |
LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, YUE Jiang, WU Jianguo, YE Qifa.
Relevance of CYP2R1 genetic polymorphism and individual therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1053-1059.
|
[7] |
HUANG Lijia, HUANG Yang, KONG Jinsong, ZHENG Xin, GONG Xiaokang, RUAN Jianwei, WANG Haibao.
Inhibition of articular cartilage degeneration by atorvastatin calcium via STAT1-caspase-3 signaling axis in rats with knee osteoarthritis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 743-748.
|
[8] |
YANG Yanan, CHEN Limei, TAO Chunlei.
Bioequivalence study of atorvastatin calcium tablets in Chinese healthy volunteers
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1258-1264.
|
[9] |
CHEN Binyao, LI Ling, ZHAO Huijia, LIU Xiaohong, QI Zhenhua, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, DONG Li, YUE Jiang, YE Qifa.
Relevance of CYP1B1 genetic polymorphism and individual therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1309-1316.
|
[10] |
ZHOU Yuan, LU Xueling, ZHAO Jun, ZHANG Li, YANG Huanjie,WANG Ning.
Polymorphism distribution of rs316019 of SLC22A2 in the Uygur population of Xinjiang
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 287-293.
|
[11] |
LIN Xiuxian, CHEN Dan, ZHAO Qing, CHEN Yao.
Genetic research on the incidence of alcoholic liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1309-1314.
|
[12] |
JIANG Hai, JIANG Guozhi, CHEN Zhong, LI Zhenjiang.
Lipid-lowering effects of combined use of curcuma longa L.extracts and atorvastatin calcium in hyperlipidemia mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 48-51.
|
[13] |
LU Yong-juan, CHEN Zhi-yun, YAN Mao-xiang, HE Bei-hui, ZHU Dan.
Effect of atorvastatin on adipokines in rats with nonalcoholic fatty liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 520-524.
|
[14] |
HU Jing, ZHU Jun-rong, YU Feng.
Efficacy and safety of warfarin dosage algorithms in clinical application:A Meta-analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 296-303.
|
[15] |
MA Xiao-qin, XIN Hua-wen, LI Yuan-qi, HUANG Hui, ZHAO Li, YU Ai-rong, LI Wei-liang, WU Xiao-chun.
Association of HGPRT activity and gene polymorphism with adverse reactions caused by azathioprine in kidney transplant recipients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 182-187.
|